Celator® Pharmaceuticals Presents Data On Combining CPX-351 With Clofarabine Or Azacytidine At The European Hematology Association Congress
Links shared publicly online about this topic.
- 1,032total visits
Celator® Pharmaceuticals Presents Data On Combining CPX-351 With Clofarabine Or Azacytidine At The European Hematology Association Congress
View full resource at medicalnewstoday.com
Most Recently Shared on July 10, 2010 at 6:04 pm By:
Celator® Pharmaceuticals Presents Data On Combining CPX-351 With Clofarabine Or Azacytidine At The European Hemato... http://mnt.to/3FXf
Also Shared By:
Positive results from Celator CPX-351 Phase 2b study on acute myeloid leukemia presented at ASCO
news-medical.net — “Celator Pharmaceuticals today announced positive clinical results in elderly patients with newly-diagnosed secondary acute myeloid leukemia (sAML) treated with CPX-351 Liposome Injection.” View full resource at news-medical.net
Most Recently Shared on June 7, 2011 at 4:49 am By:
Positive results from Celator CPX-351 Phase 2b study on acute myeloid leukemia presented at ASCO: Celator Pharma... http://bit.ly/j3kNf4
Celator granted U.S. Patent covering CombiPlex technology platform
news-medical.net — “Celator Pharmaceuticals today announced the United States Patent and Trademark Office issued U.S Patent No. 7,850,990. This patent adds to the intellectual property surrounding Celator's innovative technology platforms and products.” View full resource at news-medical.net
Most Recently Shared on December 17, 2010 at 11:58 am By:
Celator granted U.S. Patent covering CombiPlex technology platform: Celator Pharmaceuticals today announced the ... http://bit.ly/gwlUW6
Phase 2 study of CPX-351 for the treatment of acute myeloid leukemia (AML) - MPR
empr.com — “Celator Pharmaceuticals announced results from its Phase 2 trial of CPX-351 (cytarabine and daunorubicin) Liposome Injection for the treatment of adult patients with acute myeloid leukemia (AML).” View full resource at empr.com
Most Recently Shared on December 8, 2010 at 6:26 pm By:
MPR News: Phase 2 study of CPX-351 for the treatment of acute myeloid leukemia (AML): Celator Pharmaceuticals an... http://bit.ly/ejZDj3
Celator Pharmaceuticals Presents Positive Data from Phase 2 Study of CPX-351 at the American Society of Hematology Annual Meeting - Drugs.com MedNews
drugs.com — “CPX-351 produced higher remission rates, reduced early mortality, with improvements in event-free survival and overall survival in elderly patients with newly-d” View full resource at drugs.com
Most Recently Shared on December 7, 2010 at 2:12 pm By:
Drugs and Devices OW OW Health
Celator Pharmaceuticals Presents Positive Data from Phase 2 Study of CPX-351 at the American Society of He... http://bit.ly/dGWN9K #drug
Phase 2 study of CPX-351 for the treatment of acute myeloid leukemia (AML) - MPR
empr.com — “Celator announced the completed enrollment of its Phase 2 study of CPX-351 (cytarabine and daunorubicin) Liposome Injection for the treatment of adult patients with acute myeloid leukemia (AML).” View full resource at empr.com
Most Recently Shared on October 27, 2010 at 8:26 pm By:
MPR News: Phase 2 study of CPX-351 for the treatment of acute myeloid leukemia (AML): Celator announced the comple... http://bit.ly/b6ewo5
Celator® Pharmaceuticals Completes Enrollment In A Second Phase 2 Trial Of CPX-351 In Acute Myeloid Leukemia
medicalnewstoday.com — “Celator Pharmaceuticals announced that it has completed enrollment in a phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus in” View full resource at medicalnewstoday.com
Most Recently Shared on October 27, 2010 at 2:05 pm By:
Celator® Pharmaceuticals Completes Enrollment In A Second Phase 2 Trial Of CPX-351 In Acute Myeloid Leukemia http://mnt.to/3LLv
Celator gains $20M round for cancer drug dev - FierceBiotech
fiercebiotech.com — “Princeton, NJ-based Celator Pharmaceuticals has closed a $20 million Series D to back its development work on new cancer therapies. Its lead drug--CPX-351 (Cytarabine:Daunorubicin) Liposome Read more...” View full resource at fiercebiotech.com
Most Recently Shared on September 1, 2010 at 4:21 pm By:
Celator gains $20M round for cancer drug dev. http://bit.ly/dsFkfw
Celator(R) Pharmaceuticals Presents Interim Data From Phase 2 Study Of CPX-351 In Newly Diagnosed AML At American Society Of Hematology Meeting
medicalnewstoday.com — “Celator Pharmaceuticals announced that interim safety and efficacy data from its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection” View full resource at medicalnewstoday.com
Most Recently Shared on December 8, 2009 at 5:36 pm By:
MNT Clinical Trials Health News
Celator(R) Pharmaceuticals Presents Interim Data From Phase 2 Study Of CPX-351 In Newly Diagnosed AML At American S... http://bit.ly/5umdYQ
Celator® Pharmaceuticals Presents Interim Data From Phase 2
bioresearchonline.com — “Celator® pharmaceuticals presents interim data from phase 2 study of cpx-351 in newly diagnosed aml at american society of hematology meeting - celator pharmaceuticals” View full resource at bioresearchonline.com
Most Recently Shared on December 8, 2009 at 12:06 pm By:
New form of Cytarabine in chemo for AML increases Complete Response rate significantly. http://bit.ly/7Zat1Q
Interim data from Celator Pharmaceuticals' CPX-351 trial presented at the ASH meeting
news-medical.net — “Celator Pharmaceuticals today announced that interim safety and efficacy data from its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin therapy ("7+3") in patients 60-75 years of age with untreated acute myeloid leukemia (AML) were presented at the 51st American Society of Hematology (ASH) Annual Meeting in New Orleans, Louisiana (ASH Abstract # 1033).” View full resource at news-medical.net
Most Recently Shared on December 7, 2009 at 2:26 pm By:
Interim data from Celator Pharmaceuticals' CPX-351 trial presented at the ASH meeting: Celator Pharmaceuticals toda... http://bit.ly/6ThC4N
Advertisement
MNT Med Conferences
@mnt_conferences
Celator® Pharmaceuticals Presents Data On Combining CPX-351 With Clofarabine Or Azacytidine At The European Hemato... http://mnt.to/3FXf
1 year ago...